DIECI, Maria Vittoria
DIECI, Maria Vittoria
Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
2020 Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2023 Miglietta, Federica; Ragazzi, Moira; Fernandes, Bethania; Griguolo, Gaia; Massa, Davide; Girardi, Fabio; Bottosso, Michele; Bisagni, Alessandra; Zarrilli, Giovanni; Porra, Francesca; Iannaccone, Daniela; Dore, Leocadia; Gaudio, Mariangela; Santandrea, Giacomo; Fassan, Matteo; Lo Mele, Marcello; De Sanctis, Rita; Zambelli, Alberto; Bisagni, Giancarlo; Guarneri, Valentina; Dieci, Maria Vittoria
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study
2021 Dieci, M. V.; Carbognin, L.; Cumerlato, E.; Canino, F.; Griguolo, G.; Giorgi, C. A.; Amato, O.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Conte, P.; Piacentini, F.; Bria, E.; Guarneri, V.
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
2010 Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
2019 Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V.
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts
2011 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco; Guarneri, Valentina
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management
2008 Guarneri, Valentina; Giovannelli, Simona; Ficarra, G; Bettelli, Stefania Raffaella; Maiorana, Antonino; Piacentini, Federico; Barbieri, Elena; Dieci, Maria Vittoria; D'Amico, Roberto; Jovic, Gordana; Conte, Pierfranco
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS
2008 Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Piacentini, F.; Barbieri, E.; Dieci, Mv.; Jovic, G.; Conte, Pf.
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8)
2023 Dieci, M. V.; Carbognin, L.; Miglietta, F.; Canino, F.; Giorgi, C. A.; Cumerlato, E.; Amato, O.; Massa, D.; Griguolo, G.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Lo Mele, M.; Fassan, M.; Zarrilli, G.; Piacentini, F.; Bria, E.; Guarneri, V.
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis
2013 Dieci, Maria Vittoria; Barbieri, Elena; Piacentini, Federico; Ficarra, G; Bettelli, Stefania Raffaella; Dominici, Massimo; Conte, Pierfranco; Guarneri, Valentina
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y)
2017 Dieci, M. V.; Frassoldati, A.; Generali, D.; Bisagni, G.; Piacentini, F.; Cavanna, L.; Cagossi, K.; Puglisi, F.; Michelotti, A.; Berardi, R.; Banna, G.; Goubar, A.; Ficarra, G.; Griguolo, G.; Conte, P.; Guarneri, V.
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial
2021 Guarneri, V.; Giorgi, C. A.; Cinieri, S.; Bengala, C.; Mariani, G.; Bisagni, G.; Frassoldati, A.; Zamagni, C.; De Rossi, C.; Amoroso, V.; Andreetta, C.; Ferro, A.; Zambelli, A.; Gori, S.; Garrone, O.; Dieci, M. V.; Orlando, L.; Pastina, I.; Beninato, T.; Moretti, G.; Genovesi, E.; Cinefra, M.; Vicini, R.; Magni, G.; De Salvo, G. L.; Conte, P.
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials
2022 Griguolo, Gaia; Miglietta, Federica; Paré, Laia; Generali, Daniele G.; Frassoldati, Antonio; Musolino, Antonino; Spazzapan, Simon; Vernaci, Grazia; Giarratano, Tommaso; Lo Mele, Marcello; Bisagni, Giancarlo; Piacentini, Federico; Tagliafico, Enrico; Cagossi, Katia; Schiavi, Francesca; Pinato, Claudia; Prat, Aleix; Guarneri, Valentina; Dieci, Maria Vittoria
Immune characterization of breast cancer metastases: prognostic implications.
2018 Dieci, Mv; Tsvetkova, V; Orvieto, E; Piacentini, F; Ficarra, G; Griguolo, G; Miglietta, F; Giarratano, T; Omarini, C; Bonaguro, S; Cappellesso, R; Aliberti, C; Vernaci, G; Giorgi, Ca; Faggioni, G; Tasca, G; Conte, P; Guarneri, V.
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.
2021 Griguolo, G; Dieci, Mv; Paré, L; Miglietta, F; Generali, Dg; Frassoldati, A; Cavanna, L; Bisagni, G; Piacentini, F; Tagliafico, E; Cagossi, K; Ficarra, G; Prat, A; Conte, P; Guarneri, V.
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
2016 Musolino, A; Naldi, N; Dieci, Maria Vittoria; Zanoni, Daniele; Rimanti, Anita; Boggiani, D; Sgargi, P; Generali, Dg; Piacentini, Federico; Ambroggi, M; Cagossi, K; Gianni, L; Sarti, S; Bisagni, G; Ardizzoni, Andrea; Conte, Pf; Guarneri, Valentina
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
2023 Dieci, M. V.; Carbognin, L.; Miglietta, F.; Canino, F.; Giorgi, C. A.; Cumerlato, E.; Amato, O.; Massa, D.; Griguolo, G.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Lo Mele, M.; Fassan, M.; Zarrilli, G.; Piacentini, F.; Bria, E.; Guarneri, V.
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy
2010 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Conte, Pierfranco; Guarneri, Valentina
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY
2010 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, Guido; Conte, Pierfranco; Guarneri, Valentina
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
2013 Guarneri, Valentina; Dieci, Maria Vittoria; Barbieri, E; Piacentini, Federico; Omarini, Claudia; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | 1-gen-2020 | Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P | |
| A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer | 1-gen-2023 | Miglietta, Federica; Ragazzi, Moira; Fernandes, Bethania; Griguolo, Gaia; Massa, Davide; Girardi, Fabio; Bottosso, Michele; Bisagni, Alessandra; Zarrilli, Giovanni; Porra, Francesca; Iannaccone, Daniela; Dore, Leocadia; Gaudio, Mariangela; Santandrea, Giacomo; Fassan, Matteo; Lo Mele, Marcello; De Sanctis, Rita; Zambelli, Alberto; Bisagni, Giancarlo; Guarneri, Valentina; Dieci, Maria Vittoria | |
| Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study | 1-gen-2021 | Dieci, M. V.; Carbognin, L.; Cumerlato, E.; Canino, F.; Griguolo, G.; Giorgi, C. A.; Amato, O.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Conte, P.; Piacentini, F.; Bria, E.; Guarneri, V. | |
| Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer | 1-gen-2010 | Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco | |
| Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. | 1-gen-2019 | Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V. | |
| Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts | 1-gen-2011 | Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco; Guarneri, Valentina | |
| Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management | 1-gen-2008 | Guarneri, Valentina; Giovannelli, Simona; Ficarra, G; Bettelli, Stefania Raffaella; Maiorana, Antonino; Piacentini, Federico; Barbieri, Elena; Dieci, Maria Vittoria; D'Amico, Roberto; Jovic, Gordana; Conte, Pierfranco | |
| COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS | 1-gen-2008 | Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Piacentini, F.; Barbieri, E.; Dieci, Mv.; Jovic, G.; Conte, Pf. | |
| Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) | 1-gen-2023 | Dieci, M. V.; Carbognin, L.; Miglietta, F.; Canino, F.; Giorgi, C. A.; Cumerlato, E.; Amato, O.; Massa, D.; Griguolo, G.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Lo Mele, M.; Fassan, M.; Zarrilli, G.; Piacentini, F.; Bria, E.; Guarneri, V. | |
| Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis | 1-gen-2013 | Dieci, Maria Vittoria; Barbieri, Elena; Piacentini, Federico; Ficarra, G; Bettelli, Stefania Raffaella; Dominici, Massimo; Conte, Pierfranco; Guarneri, Valentina | |
| Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) | 1-gen-2017 | Dieci, M. V.; Frassoldati, A.; Generali, D.; Bisagni, G.; Piacentini, F.; Cavanna, L.; Cagossi, K.; Puglisi, F.; Michelotti, A.; Berardi, R.; Banna, G.; Goubar, A.; Ficarra, G.; Griguolo, G.; Conte, P.; Guarneri, V. | |
| Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial | 1-gen-2021 | Guarneri, V.; Giorgi, C. A.; Cinieri, S.; Bengala, C.; Mariani, G.; Bisagni, G.; Frassoldati, A.; Zamagni, C.; De Rossi, C.; Amoroso, V.; Andreetta, C.; Ferro, A.; Zambelli, A.; Gori, S.; Garrone, O.; Dieci, M. V.; Orlando, L.; Pastina, I.; Beninato, T.; Moretti, G.; Genovesi, E.; Cinefra, M.; Vicini, R.; Magni, G.; De Salvo, G. L.; Conte, P. | |
| Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials | 1-gen-2022 | Griguolo, Gaia; Miglietta, Federica; Paré, Laia; Generali, Daniele G.; Frassoldati, Antonio; Musolino, Antonino; Spazzapan, Simon; Vernaci, Grazia; Giarratano, Tommaso; Lo Mele, Marcello; Bisagni, Giancarlo; Piacentini, Federico; Tagliafico, Enrico; Cagossi, Katia; Schiavi, Francesca; Pinato, Claudia; Prat, Aleix; Guarneri, Valentina; Dieci, Maria Vittoria | |
| Immune characterization of breast cancer metastases: prognostic implications. | 1-gen-2018 | Dieci, Mv; Tsvetkova, V; Orvieto, E; Piacentini, F; Ficarra, G; Griguolo, G; Miglietta, F; Giarratano, T; Omarini, C; Bonaguro, S; Cappellesso, R; Aliberti, C; Vernaci, G; Giorgi, Ca; Faggioni, G; Tasca, G; Conte, P; Guarneri, V. | |
| Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. | 1-gen-2021 | Griguolo, G; Dieci, Mv; Paré, L; Miglietta, F; Generali, Dg; Frassoldati, A; Cavanna, L; Bisagni, G; Piacentini, F; Tagliafico, E; Cagossi, K; Ficarra, G; Prat, A; Conte, P; Guarneri, V. | |
| Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer | 1-gen-2016 | Musolino, A; Naldi, N; Dieci, Maria Vittoria; Zanoni, Daniele; Rimanti, Anita; Boggiani, D; Sgargi, P; Generali, Dg; Piacentini, Federico; Ambroggi, M; Cagossi, K; Gianni, L; Sarti, S; Bisagni, G; Ardizzoni, Andrea; Conte, Pf; Guarneri, Valentina | |
| Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation | 1-gen-2023 | Dieci, M. V.; Carbognin, L.; Miglietta, F.; Canino, F.; Giorgi, C. A.; Cumerlato, E.; Amato, O.; Massa, D.; Griguolo, G.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Lo Mele, M.; Fassan, M.; Zarrilli, G.; Piacentini, F.; Bria, E.; Guarneri, V. | |
| Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy | 1-gen-2010 | Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Conte, Pierfranco; Guarneri, Valentina | |
| KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY | 1-gen-2010 | Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, Guido; Conte, Pierfranco; Guarneri, Valentina | |
| Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients | 1-gen-2013 | Guarneri, Valentina; Dieci, Maria Vittoria; Barbieri, E; Piacentini, Federico; Omarini, Claudia; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco |